Susan G. Komen® is committed to bridging financial gaps for underserved individuals coping with breast cancer across the country. Offered in partnership with CancerCare, the Susan G. Komen Treatment Assistance Program is open to low-income, underinsured or uninsured women who are actively undergoing treatment for breast cancer.
CancerCare and Savor Health® Announce Partnership and Introduce Ina™, the Intelligent Nutrition Assistant
In partnership with Savor Health®, we are happy to introduce Ina™, the Intelligent Nutrition Assistant.
CancerCare recently received a $700,000 grant from The New York Community Trust to provide financial assistance to low-income New Yorkers affected by cancer.
CancerCare’s Vilmarie Rodriguez, Director of Patient Assistance Programs, Receives Emerald Leader Award of the National Association of Social Workers
CancerCare is thrilled to announce Vilmarie Rodriguez, Director of Patient Assistance Programs, LCSW, is the recipient of the Emerald Leader Award of the National Association of Social Workers – New York City Chapter (NASW-NYC).
“The Sephora Brave Beauty classes are special for so many reasons,” said Maryrose Mongelli, LMSW CancerCare’s Women’s Cancers Program Coordinator. “It’s all about making these women feel good and confident about themselves, throughout their difficult journey.”
For the third year, CancerCare, in partnership with Flatiron Health, hosted a fun-filled Winter Wonderland Holiday Party. The party was open to all of CancerCare’s clients, including families, adults and caregivers affected by cancer. Flatiron Health graciously hosted 120+ children, adults and staff members in their office space in the Soho neighborhood of New York City.
CancerCare recently held a second lung cancer roundtable discussion titled, “The Role of Lung Advocacy Organizations in Biomarker Testing.”
On Wednesday, May 2, four makeup artists from Sephora’s Herald Square store visited CancerCare’s National Office to offer complementary consultations to people with cancer and their loved ones.
CancerCare, in partnership with LUNGevity Foundation, is interested in understanding the burden of financial toxicity associated with lung cancer diagnosis and treatment.
Triple negative breast cancer (TNBC) is a breast cancer subtype, which is found in 10-20% of all breast cancer diagnoses each year. The name originates from tumors found in the breast that are estrogen receptor-negative, progesterone receptor-negative, and human epidermal growth factor receptor 2-negative. In other words, TNBC tumors do not exhibit any of these three receptors. Although these tumors do not respond to receptor-specific treatments, they are typically responsive to chemotherapy.